Abstract
Currently, Coronary Artery Disease (CAD) is considered as a major ailment in humans with widespread prevalence. CAD also accounts for high mortality rates around the world that involves several known risk factors. Recently, it was discovered that epicardial adipose tissue (EAT) and its secretory adipokines play an imperative role in the development of CAD. Among the secretory adipokines, chemerin , a serpentine chemotactic agonist has been identified as one of the factor which contributes for the progression of CAD. Since serum chemerin levels are elevated during CAD condition, it is being considered to be a valiant marker but then the chimeric property of chemerin is yet to be explored. Though chemerin has been identified as one of the factors responsible for the development of CAD, it is still being studied at the marker level. This review aims to study whether chemerin can only be used as a marker or can it also be used as a novel target for treating or suppressing or delaying the progression of coronary artery disease.
Highlights
1.1 Coronary artery disease (CAD) known to be the disease of rich in past, has been classified by World Health Organization as the disease of 21st century with high prevalence that can occur to almost all population without rationality.Coronary Artery Disease (CAD) can be characterized as a disease with high morbidity, mortality, reduced quality of life and substantial economic burden[1]
David R Greaves and his team had invented C-terminal end of chemerin protein which can be used in the treatment of inflammation and/or endotoxic shock and or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject[26] Trevor et al, had invented pyrrolidinone carboxamide derivatives that can be used as a therapeutic agent for treating various inflammatory diseases and metabolic syndromes including but not limited to obesity and cardiovascular diseases by modulating ChemR23, a G-PROTEIN COUPLED RECEPTOR (GPCR) to chemerin 27
Upon treatment of the stimulated adipocytes with aspirin, chemerin expression did not reduce which suggest that aspirin reduces inflammation in adipose tissue and in turn it reduces adipocyte expression of chemerin[35]. This demonstrates that chemerin secreted by adipose tissue, especially Epicardial adipose tissue establishes itself as a factor which is actively involved in the progression or development of CAD
Summary
1.1 Coronary artery disease (CAD) known to be the disease of rich in past, has been classified by World Health Organization as the disease of 21st century with high prevalence that can occur to almost all population without rationality. CAD can be characterized as a disease with high morbidity, mortality, reduced quality of life and substantial economic burden[1]. In comparison with western countries and other parts across the world, Asia, has raised itself as a hub of CAD with increased premature mortality rates[5]. This review will focus on the chemokine chemerin and study whether it can be used only as a marker or can it be used as target for the treatment of Coronary Artery Disease (CAD)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Biomedical and Advance Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
